Oncolytic virus-driven immune modulation and therapeutic combinations: Tackling the “Cold Tumor Space”
Xtalks Webinar Presentation
This webinar will provide a short introduction to immuno-oncology, the shortcomings of current standard of care checkpoint inhibitors and the mechanism of action of oncolytic virotherapies. We will discuss selective replication of the oncolytic virus VSV-GP in tumor cells, tumor cell lysis and reshaping of the tumor microenvironment. The results from this study explore the potential of VSV-GP as an immuno-oncology enabler for a broad range of cancers in poorly “T-cell inflamed” tumors and highlight VSV-GP as a non-mutagenic virus that synergizes with other immunotherapies as well as targeted therapies.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.